Abbott Laboratories (NYSE:ABT) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Abbott Laboratories (NYSE:ABT) have been given a consensus recommendation of “Moderate Buy” by the twenty-seven research firms that are presently covering the firm, Marketbeat reports. Four research analysts have rated the stock with a hold recommendation, twenty have issued a buy recommendation and three have given a strong buy recommendation to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $119.50.

Several brokerages have recently commented on ABT. BTIG Research increased their price target on shares of Abbott Laboratories from $131.00 to $134.00 and gave the stock a “buy” rating in a research note on Friday, July 17th. Citigroup upped their price objective on shares of Abbott Laboratories from $108.00 to $112.00 and gave the stock a “buy” rating in a report on Friday, July 17th. Wolfe Research raised shares of Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 target price on the stock in a research report on Thursday, August 13th. JPMorgan Chase & Co. boosted their price target on Abbott Laboratories from $110.00 to $120.00 and gave the stock an “overweight” rating in a research report on Friday, July 17th. Finally, The Goldman Sachs Group lowered their price objective on Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating on the stock in a report on Wednesday, May 27th.

Abbott Laboratories Stock Performance

Shares of ABT stock opened at $102.08 on Friday. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $137.49. The stock’s 50-day moving average is $105.60 and its two-hundred day moving average is $99.85. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. The firm has a market cap of $176.63 billion, a P/E ratio of 33.03, a PEG ratio of 1.89 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.03. The business had revenue of $12.59 billion during the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The firm’s revenue was up 13.0% on a year-over-year basis. During the same period in the previous year, the company earned $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Analysts predict that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Institutional Trading of Abbott Laboratories

Institutional investors and hedge funds have recently modified their holdings of the company. Nia Impact Advisors LLC grew its holdings in shares of Abbott Laboratories by 2.2% during the second quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker’s stock worth $504,000 after purchasing an additional 79 shares during the last quarter. Riggs Asset Managment Co. Inc. increased its position in Abbott Laboratories by 9.3% in the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 1,031 shares of the healthcare product maker’s stock valued at $140,000 after acquiring an additional 88 shares in the last quarter. Eley Financial Management Inc raised its stake in shares of Abbott Laboratories by 0.9% in the fourth quarter. Eley Financial Management Inc now owns 10,817 shares of the healthcare product maker’s stock worth $1,355,000 after acquiring an additional 92 shares during the last quarter. Kelleher Financial Advisors grew its stake in shares of Abbott Laboratories by 2.9% during the third quarter. Kelleher Financial Advisors now owns 3,301 shares of the healthcare product maker’s stock valued at $442,000 after purchasing an additional 93 shares during the last quarter. Finally, Copley Financial Group Inc. increased its holdings in shares of Abbott Laboratories by 2.1% in the fourth quarter. Copley Financial Group Inc. now owns 4,435 shares of the healthcare product maker’s stock valued at $556,000 after purchasing an additional 93 shares in the last quarter. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Abbott Laboratories Company Profile

Abbott Laboratories (NYSE: ABT) is a global healthcare company that develops, manufactures and sells medical products and technologies. Its operations span four principal areas: medical devices, diagnostics, established pharmaceutical products and nutrition. Abbott serves healthcare providers, institutions and consumers in markets around the world.

The company’s medical device portfolio includes products for cardiovascular care, diabetes management and other specialties. Its diagnostics business provides laboratory systems, tests and point-of-care solutions, while its nutrition products include infant, child and adult nutritional offerings sold under brands such as Similac, Ensure and Pedialyte.